{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T04:09:06Z","timestamp":1792382946678,"version":"4.4.0"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,25]]},"DOI":"10.1093\/ajhp\/zxy022","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T20:59:09Z","timestamp":1548449949000},"page":"130-135","source":"Crossref","is-referenced-by-count":74,"title":["Abaloparatide: A new pharmacological option for osteoporosis"],"prefix":"10.1093","volume":"76","author":[{"given":"Allyson","family":"Sleeman","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University Health Care System, Augusta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer N","family":"Clements","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Presbyterian College School of Pharmacy, Clinton, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,1,17]]},"reference":[{"key":"2019061104404577500_CIT0001","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician\u2019s guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"key":"2019061104404577500_CIT0002","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1002\/jbmr.2269","article-title":"The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine","volume":"29","author":"Wright","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"suppl 4","key":"2019061104404577500_CIT0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161435.GL","article-title":"AACE\/ACE clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis","volume":"22","author":"Camacho","year":"2016","journal-title":"Endocr Pract"},{"key":"2019061104404577500_CIT0004","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"2019061104404577500_CIT0005","article-title":"Tymlos (abaloparatide) package insert","year":"2017"},{"key":"2019061104404577500_CIT0006","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0030-5898(20)31563-7","article-title":"Calcium homeostasis","volume":"21","author":"Boden","year":"1990","journal-title":"Orthop Clin North Am"},{"key":"2019061104404577500_CIT0007","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2019061104404577500_CIT0008","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs. placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"2019061104404577500_CIT0009","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","article-title":"Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial","volume":"92","author":"Cosman","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"2019061104404577500_CIT0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/jbmr.2991","article-title":"Effects of abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors","volume":"32","author":"Cosman","year":"2017","journal-title":"J Bone Miner Res"},{"key":"2019061104404577500_CIT0011","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bone.2016.11.004","article-title":"Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial","volume":"97","author":"Moreira","year":"2017","journal-title":"Bone"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/76\/3\/130\/28791374\/zxy022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T00:09:17Z","timestamp":1662854957000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/76\/3\/130\/5290437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,17]]},"references-count":11,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,1,17]]},"published-print":{"date-parts":[[2019,1,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxy022","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2,1]]},"published":{"date-parts":[[2019,1,17]]}}}